Annual report for Strides Pharma Science Ltd. for FY-2023
25-05-2023
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Advertisement - Notice for transferring of equity shares to Investor Education and Protection Fund (IEPF)24-05-2023
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Earnings Call for discussion of audited financial results for the quarter and year ended March 31, 2023.23-05-2023
Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation pursuant to Regulation 39 (3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 201519-05-2023
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Strides Puducherry facility receives Establishment Inspection Report (EIR) from USFDA confirming the reclassification of the site from Official Action Indicated (OAI) to Voluntary Action Indicated (VAI)19-05-2023
Strides Pharma Science Ltd - 532531 - Board Meeting Intimation for Announcement Of Board Meeting Under Regulation 29 Of SEBI Listing Regulations
Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2023 ,inter alia, to consider and approve Announcement of Board Meeting under Regulation 29 of SEBI Listing Regulations18-05-2023
Strides Pharma Science Ltd - 532531 - Submission Of Statement Of Deviation/ Variation Pursuant To Regulation 32 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Submission of Statement of Deviation/ Variation pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201505-05-2023
Strides Pharma Science Ltd - 532531 - Submission Of Statement Of Deviation/ Variation Pursuant To Regulation 32 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Submission of Statement of Deviation/ Variation pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201505-05-2023
Strides Pharma Science Ltd - 532531 - Submission Of Statement Of Deviation/ Variation Pursuant To Regulation 32 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Submission of Statement of Deviation/ Variation pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201505-05-2023
Strides Pharma, Orbicular Pharmaceutical to develop nasal sprays for global markets
The partnership will commercialise four nasal sprays with a combined global market size in excess of $400 million03-05-2023